Table 1.
Clinical features of 234 cases with non-alcoholic fatty liver disease (NAFLD)
| Clinical parameters | Cases (mean ± SDa) |
|---|---|
| Weight (kg) | 84.11 ± 16.96 |
| Height (m) | 1.70 ± 0.09 |
| Waist length (cm) | 100.87 ± 11.44 |
| Obesity (BMI >30 kg/m2) | 98 (34 %) |
| Diabetes [n (%)] | 41 (14 %) |
| Hypertension [n (%)] | 93 (32 %) |
| Glucose level (mg/dl) | 97.73 ± 32.43 |
| Fasting insulin level (mmol/l) | 15.85 ± 10.87 |
| HOMA score | 3.88 ± 3.34 |
| HOMA score >2.5 [n (%)] | 117 (40 %) |
| Total cholesterol (mg/dl) | 196.25 ± 47.18 |
| HDL (mg/dl) | 46.96 ± 11.51 |
| Hypercholesterolemia [n (%)] | 124 (43 %) |
| Triglyceride level (mg/dl) | 145.68 ± 82.94 |
| Hypertriglyceridemia [n (%)] | 101 (35 %) |
| MS ATP IIIb [n (%)] | 64 (22 %) |
| AST (IU/l) | 38.65 ± 33.49 |
| ALT (IU/l) | 55.91 ± 40.58 |
| AST/ALT ratio | 0.85 ± 0.68 |
| AST/ALT ratio ≥1.0 [n (%)] | 48 (17 %) |
| GGT (IU/l) | 67.33 ± 88.06 |
| Alkaline phosphatase (IU/l) | 174.58 ± 83.45 |
| Total bilirubin (μmol/l) | 1.11 ± 1.64 |
| Albumin (g/dl) | 4.49 ± 0.45 |
| INR | 1.08 ± 0.31 |
| PLT (×103/ml) | 232.79 ± 72.24 |
aStandard deviation
bMetabolic syndrome—Adult Treatment Panel III (ATP III) criteria: abdominal obesity, waist circumference >102 cm (men) or >88 cm (women); hyperglycemia, fasting blood glucose ≥110 mg/dl or previously diagnosed type 2 diabetes; hypertriglyceridemia, triglycerides ≥150 mg/dl or current treatment for this abnormality; hypertension, blood pressure ≥130/≥85 mmHg or treatment for previously diagnosed hypertension); and low HDL cholesterol, <40 mg/dl (men) or <50 mg/dl (women) or specific treatment for this abnormality). Patients meeting >3 of these criteria were considered to have the metabolic syndrome